Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone secreted in response to nutrients. GLP-1 is used in the therapeutic management of diabetes because of its gluco-regulatory effects, including augmentation of glucose-stimulated insulin secretion, suppression of postprandial glucagon secretion, delayed gastric emptying, and hypothalamus-mediated satiety of appetite. GLP-1 receptors are expressed not only in islet cells, kidney, lung, brain, and gastrointestinal tract, but also in the heart.
Citation: Zeraatian S, Salehiomran A, Aghdam RM, Tafti SHA, Ghiasi SR (2015) Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs. Cardiol Pharmacol 4:159.